XML 47 R27.htm IDEA: XBRL DOCUMENT
v3.25.4

Segments of Business and Geographic Areas | 12 Months Ended
--- | ---
Dec. 28, 2025
Segment Reporting [Abstract] |
Segments of Business and Geographic Areas | Segments of Business and Geographic Areas The Company is organized into three reportable business segments: Self Care, Skin Health and Beauty, and Essential Health. The Company’s Chief Operating Decision Maker (the “CODM”), the Chief Executive Officer, uses Segment adjusted operating income as the measure of profit or loss and to evaluate the performance of the Company’s segments. For each segment, the CODM uses this information to assist in evaluating underlying trends, to monitor budget and forecast versus actual results, to make investment decisions to allocate resources both in total, and between the segments, and to make key segment personnel decisions. Segment profit is based on Operating income, excluding depreciation, amortization of intangible assets, Separation-related costs, restructuring expenses and operating model optimization initiatives, impairment charges, the impact of the conversion of stock-based awards, issuance of Founder Shares, Proposed Transaction costs (as defined below), Other operating (income) expense, net, and unallocated general corporate administrative expenses (referred to herein as “Segment adjusted operating income”), as the CODM excludes these items in assessing segment financial performance. General corporate/unallocated expenses, which include expenses related to treasury, legal operations, and certain other expenses, along with gains and losses related to the overall management of the Company, are not allocated to the segments. In assessing segment performance and managing operations, the CODM does not review segment assets. The Company operates the business through the following three reportable business segments based on product categories:
Reportable Segments | Product Categories
Self Care | Cough, Cold, and Allergy
| Pain Care
| Other Self Care (Digestive Health, Smoking Cessation, Eye Care, and Other)
Skin Health and Beauty | Face and Body Care
| Hair, Sun, and Other
Essential Health | Oral Care
| Baby Care
| Other Essential Health (Women’s Health, Wound Care, and Other)
The Company’s product categories as a percentage of Net sales for the fiscal twelve months ended December 28, 2025, December 29, 2024, and December 31, 2023 were as follows:
|  |  |  | Fiscal Twelve Months Ended
Product Categories |  |  |  |  |  | December 28, 2025 |  | December 29, 2024 |  | December 31, 2023
Cough, Cold, and Allergy |  |  |  |  |  | 13 | % |  | 14 | % |  | 13 | %
Pain Care |  |  |  |  |  | 13 |  |  | 13 |  |  | 14 |
Other Self Care |  |  |  |  |  | 16 |  |  | 15 |  |  | 15 |
Face and Body Care |  |  |  |  |  | 19 |  |  | 19 |  |  | 20 |
Hair, Sun, and Other |  |  |  |  |  | 8 |  |  | 8 |  |  | 9 |
Oral Care |  |  |  |  |  | 11 |  |  | 11 |  |  | 10 |
Baby Care |  |  |  |  |  | 9 |  |  | 9 |  |  | 9 |
Other Essential Health |  |  |  |  |  | 11 |  |  | 11 |  |  | 10 |
Total |  |  |  |  |  | 100 | % |  | 100 | % |  | 100 | %
Segment Net Sales and Segment Adjusted Operating Income Segment net sales and Segment adjusted operating income for the fiscal twelve months ended December 28, 2025, December 29, 2024, and December 31, 2023 were as follows:
|  | Fiscal Twelve Months Ended |  |
|  | December 28, 2025 |  | December 29, 2024 |  | December 31, 2023 |  |
(Dollars in Millions) |  | Self Care |  | Skin Health and Beauty |  | Essential Health |  | Total |  | Self Care |  | Skin Health and Beauty |  | Essential Health |  | Total |  | Self Care |  | Skin Health and Beauty |  | Essential Health |  | Total |  |  |  |
Net sales |  | $ | 6,378 |  |  | $ | 4,114 |  |  | $ | 4,632 |  |  | $ | 15,124 |  |  | $ | 6,527 |  |  | $ | 4,240 |  |  | $ | 4,688 |  |  | $ | 15,455 |  |  | $ | 6,451 |  |  | $ | 4,378 |  |  | $ | 4,615 |  |  | $ | 15,444 |  |  |  |  |
Segment adjusted Cost of sales(1) |  | 2,285 |  |  | 1,671 |  |  | 2,056 |  |  | 6,012 |  |  | 2,287 |  |  | 1,738 |  |  | 2,102 |  |  | 6,127 |  |  | 2,249 |  |  | 1,952 |  |  | 2,228 |  |  | 6,429 |  |  |  |  |
Other segment expense items(2) |  | 1,984 |  |  | 1,966 |  |  | 1,400 |  |  | 5,350 |  |  | 2,067 |  |  | 1,895 |  |  | 1,424 |  |  | 5,386 |  |  | 1,903 |  |  | 1,747 |  |  | 1,376 |  |  | 5,026 |  |  |  |  |
Segment adjusted operating income |  | $ | 2,109 |  |  | $ | 477 |  |  | $ | 1,176 |  |  | $ | 3,762 |  |  | $ | 2,173 |  |  | $ | 607 |  |  | $ | 1,162 |  |  | $ | 3,942 |  |  | $ | 2,299 |  |  | $ | 679 |  |  | $ | 1,011 |  |  | $ | 3,989 |  |  |  |  |
Reconciliation to Income before taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Less: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Depreciation(3) |  |  |  |  |  |  |  | 300 |  |  |  |  |  |  |  |  | 329 |  |  |  |  |  |  |  |  | 305 |  |  |  |  |
Amortization of intangible assets(4) |  |  |  |  |  |  |  | 257 |  |  |  |  |  |  |  |  | 269 |  |  |  |  |  |  |  |  | 322 |  |  |  |  |
Separation-related costs(5) |  |  |  |  |  |  |  | 88 |  |  |  |  |  |  |  |  | 296 |  |  |  |  |  |  |  |  | 468 |  |  |  |  |
Restructuring expenses and operating model optimization initiatives(6) |  |  |  |  |  |  |  | 335 |  |  |  |  |  |  |  |  | 221 |  |  |  |  |  |  |  |  | 32 |  |  |  |  |
Impairment charges(7) |  |  |  |  |  |  |  | 23 |  |  |  |  |  |  |  |  | 578 |  |  |  |  |  |  |  |  | — |  |  |  |  |
Conversion of stock-based awards(8) |  |  |  |  |  |  |  | 7 |  |  |  |  |  |  |  |  | 39 |  |  |  |  |  |  |  |  | 55 |  |  |  |  |
Founder Shares(9) |  |  |  |  |  |  |  | 7 |  |  |  |  |  |  |  |  | 29 |  |  |  |  |  |  |  |  | 9 |  |  |  |  |
Proposed Transaction costs(10) |  |  |  |  |  |  |  | 25 |  |  |  |  |  |  |  |  | — |  |  |  |  |  |  |  |  | — |  |  |  |  |
Other operating (income) expense, net |  |  |  |  |  |  |  | (23) |  |  |  |  |  |  |  |  | 26 |  |  |  |  |  |  |  |  | (10) |  |  |  |  |
General corporate/unallocated expenses |  |  |  |  |  |  |  | 329 |  |  |  |  |  |  |  |  | 314 |  |  |  |  |  |  |  |  | 296 |  |  |  |  |
Operating income |  |  |  |  |  |  |  | $ | 2,414 |  |  |  |  |  |  |  |  | $ | 1,841 |  |  |  |  |  |  |  |  | $ | 2,512 |  |  |  |  |
Other expense, net |  |  |  |  |  |  |  | 36 |  |  |  |  |  |  |  |  | 48 |  |  |  |  |  |  |  |  | 72 |  |  |  |  |
Interest expense, net |  |  |  |  |  |  |  | 379 |  |  |  |  |  |  |  |  | 378 |  |  |  |  |  |  |  |  | 250 |  |  |  |  |
Income before taxes |  |  |  |  |  |  |  | $ | 1,999 |  |  |  |  |  |  |  |  | $ | 1,415 |  |  |  |  |  |  |  |  | $ | 2,190 |  |  |  |  |
(1) The Company defines Segment adjusted cost of sales as Cost of sales adjusted for amortization of intangible assets, Separation-related costs, conversion of stock-based awards, Founder Shares, operating model optimization initiatives, and general corporate/unallocated expenses. (2) Other segment expense items for each reportable business segment include brand support, employee-related costs, shipping and handling costs, research and development costs, and certain other operating expenses (income). (3) Depreciation consists of depreciation of property, plant, and equipment and amortization of integration and development costs capitalized in connection with cloud computing arrangements. (4) Relates to the amortization of definite-lived intangible assets (primarily trademarks, trade names, and customer lists) over their estimated useful lives. (5) Separation-related costs includes depreciation expense on Separation-related assets for the fiscal twelve months ended December 29, 2024. See Note 1, “Description of the Company and Summary of Significant Accounting Policies—Separation-Related Costs,” for additional information regarding Separation-related costs. (6) Restructuring expenses and operating model optimization initiatives relate to the 2024 Multi-Year Restructuring Initiative in the fiscal twelve months ended December 29, 2024 and December 28, 2025 (as defined in Note 19, “Restructuring Expenses and Operating Model Optimization Initiatives”). See Note 19, “Restructuring Expenses and Operating Model Optimization Initiatives,” for additional information. (7) Impairment charges for the fiscal twelve months ended December 28, 2025 includes $23 million recognized in connection with the ORSL® trade name following regulatory changes in India. Impairment charges for the fiscal twelve months ended December 29, 2024 includes $488 million recognized in relation to Dr.Ci:Labo® long-lived assets, $68 million recognized on the held for sale asset associated with the Company’s former corporate headquarters in Skillman, New Jersey, and $22 million recognized on certain software development assets. See Note 1, “Description of the Company and Summary of Significant Accounting Policies—Impairment of Long-Lived Assets,” for additional information. (8) Segment adjusted operating income excludes the impact of the conversion of stock-based awards that occurred on August 23, 2023 (see Note 11, “Stock-Based Compensation” for additional information). The adjustment represents the net impact of the gain on reversal of previously recognized stock-based compensation expense, offset by stock-based compensation expense recognized in the fiscal twelve months ended December 28, 2025, December 29, 2024, and December 31, 2023 relating to employee services provided prior to the Separation. (9) On October 2, 2023, the Founder Shares were granted to all Kenvue employees in the form of stock options and PSUs to executive officers and either stock options and PSUs or RSUs to non-executive individuals. (10) Proposed Transaction costs primarily consist of expenses incurred in connection with the Proposed Transaction, including advisory fees, legal costs, and other professional service costs (the “Proposed Transaction costs”). Depreciation and Amortization Depreciation and amortization by reportable business segment for the fiscal twelve months ended December 28, 2025, December 29, 2024, and December 31, 2023 were as follows:
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Fiscal Twelve Months Ended
(Dollars in Millions) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | December 28, 2025 |  | December 29, 2024 |  | December 31, 2023
Self Care |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 204 |  |  | $ | 217 |  |  | $ | 202 |
Skin Health and Beauty |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 123 |  |  | 174 |  |  | 230 |
Essential Health |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 230 |  |  | 231 |  |  | 195 |
Total depreciation and amortization(1) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 557 |  |  | $ | 622 |  |  | $ | 627 |
(1) Depreciation consists of depreciation of property, plant, and equipment and amortization of integration and development costs capitalized in connection with cloud computing arrangements. Amortization relates to the amortization of intangible assets. Geographic Information Net sales are attributed to a geographic region based on the location of the customer and for the fiscal twelve months ended December 28, 2025, December 29, 2024, and December 31, 2023 were as follows:
|  |  |  |  |  | Fiscal Twelve Months Ended
(Dollars in Millions) |  |  |  |  |  | December 28, 2025 |  | December 29, 2024 |  | December 31, 2023
North America(1) |  |  |  |  |  | $ | 7,259 |  |  | $ | 7,579 |  |  | $ | 7,610 |
Europe, Middle East, and Africa |  |  |  |  |  | 3,721 |  |  | 3,559 |  |  | 3,388 |
Asia-Pacific |  |  |  |  |  | 2,775 |  |  | 2,974 |  |  | 3,107 |
Latin America |  |  |  |  |  | 1,369 |  |  | 1,343 |  |  | 1,339 |
Total Net sales |  |  |  |  |  | $ | 15,124 |  |  | $ | 15,455 |  |  | $ | 15,444 |
(1) Includes U.S. Net sales in the fiscal twelve months ended December 28, 2025, December 29, 2024, and December 31, 2023 of $6,460 million, $6,719 million, and $6,767 million, respectively. Long-lived assets consisting of property, plant, and equipment, net of accumulated depreciation as of December 28, 2025 and December 29, 2024 were as follows:
(Dollars in Millions) |  | December 28, 2025 |  | December 29, 2024
North America(1) |  | $ | 1,156 |  |  | $ | 922 |
Europe, Middle East, and Africa |  | 536 |  |  | 432 |
Asia-Pacific |  | 308 |  |  | 297 |
Latin America |  | 212 |  |  | 198 |
Total long-lived assets |  | $ | 2,212 |  |  | $ | 1,849 |
(1) Includes U.S. long-lived assets as of December 28, 2025 and December 29, 2024 of $1,078 million and $848 million, respectively. Major Customers One of the Company’s customers accounted for approximately 12% of total Net sales in each of the fiscal twelve months ended December 28, 2025, December 29, 2024, and December 31, 2023.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 14: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration